Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Protein pathway analysis to study development-dependent effects of acute and repeated trimethyltin (TMT) treatments in 3D rat brain cell cultures.

Schvartz D, González-Ruiz V, Walter N, Antinori P, Jeanneret F, Tonoli D, Boccard J, Zurich MG, Rudaz S, Monnet-Tschudi F, Sandström J, Sanchez JC.

Toxicol In Vitro. 2019 Jun 7;60:281-292. doi: 10.1016/j.tiv.2019.05.020. [Epub ahead of print]

PMID:
31176792
2.

Navigating in vitro bioactivity data by investigating available resources using model compounds.

Ilmjärv S, Augsburger F, Bolleman JT, Liechti R, Bridge AJ, Sandström J, Jaquet V, Xenarios I, Krause KH.

Sci Data. 2019 Apr 29;6(1):45. doi: 10.1038/s41597-019-0046-1. No abstract available.

3.

An Integrative Multi-Omics Workflow to Address Multifactorial Toxicology Experiments.

González-Ruiz V, Schvartz D, Sandström J, Pezzatti J, Jeanneret F, Tonoli D, Boccard J, Monnet-Tschudi F, Sanchez JC, Rudaz S.

Metabolites. 2019 Apr 24;9(4). pii: E79. doi: 10.3390/metabo9040079.

4.

In vitro models to study insulin and glucocorticoids modulation of trimethyltin (TMT)-induced neuroinflammation and neurodegeneration, and in vivo validation in db/db mice.

Sandström J, Kratschmar DV, Broyer A, Poirot O, Marbet P, Chantong B, Zufferey F, Dos Santos T, Boccard J, Chrast R, Odermatt A, Monnet-Tschudi F.

Arch Toxicol. 2019 Jun;93(6):1649-1664. doi: 10.1007/s00204-019-02455-0. Epub 2019 Apr 16.

PMID:
30993381
5.

Preclinical hazard evaluation strategy for nanomedicines.

Siegrist S, Cörek E, Detampel P, Sandström J, Wick P, Huwyler J.

Nanotoxicology. 2019 Feb;13(1):73-99. doi: 10.1080/17435390.2018.1505000. Epub 2018 Sep 5.

PMID:
30182784
6.

Functional studies of the yeast med5, med15 and med16 mediator tail subunits.

Larsson M, Uvell H, Sandström J, Rydén P, Selth LA, Björklund S.

PLoS One. 2013 Aug 22;8(8):e73137. doi: 10.1371/journal.pone.0073137. eCollection 2013.

7.

Degeneration of the mouse retina upon dysregulated activity of serum response factor.

Sandström J, Heiduschka P, Beck SC, Philippar U, Seeliger MW, Schraermeyer U, Nordheim A.

Mol Vis. 2011 Apr 29;17:1110-27.

Supplemental Content

Loading ...
Support Center